Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Authors
Category Primary study
JournalBlood
Year 2021
This article has no abstract
Epistemonikos ID: a7e2a48ced6ceef91ce72c69b4087de432732d68
First added on: Feb 13, 2025